Royalty Pharma (RPRX) announced the appointment of Vlad Coric to the company’s board of directors, effective immediately. Vlad Coric is the chairman and CEO of Biohaven (BHVN).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma pullback a buying opportunity, says Citi
- Royalty Pharma’s Strong Portfolio and Future Growth Potential Underpin Buy Rating
- Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition
- Royalty Pharma announces R&D funding collaboration with Biogen
- Royalty Pharma PLC Reports Strong 2024 Financial Results